Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing

Cancer Cytopathology

Volumn 123, Issue 8, 2015, Pages 471-479

  Paskaš, Svetlana ^a   Jankovic, Jelena ^a   Živaljevic, Vladan ^a   Tatic, Svetislav ^a   Božic, Vesna ^b   Nikolic, Aleksandra ^a   Radojkovic, Dragica ^a   Savin, Svetlana ^a   Cvejic, Dubravka ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

BRAF; fine needle aspirates; galectin 3; indeterminate cytology; microRNA 221 (miR 221); microRNA 222 (miR 222); thyroid cancer

Indexed keywords

GALECTIN 3; MICRORNA 221; MICRORNA 222; B RAF KINASE; BRAF PROTEIN, HUMAN; MICRORNA; TUMOR MARKER;

ARTICLE; BRAF GENE; CLINICAL EVALUATION; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MOLECULAR DIAGNOSTICS; ONCOGENE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROID NODULE; THYROIDECTOMY; UPREGULATION; VALIDITY; ADULT; AREA UNDER THE CURVE; CELL TRANSFORMATION; COMPARATIVE STUDY; CYTODIAGNOSIS; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; THYROID TUMOR;

ADULT; AREA UNDER CURVE; BIOMARKERS, TUMOR; BIOPSY, FINE-NEEDLE; CELL TRANSFORMATION, NEOPLASTIC; CYTODIAGNOSIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROID NODULE;

EID: 84952051465     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21554     Document Type: Article

References (35)

1. Hegedus L,. Clinical practice. The thyroid nodule. N Engl J Med. 2004; 351: 1764-1771.
2. Cooper DS, Doherty GM, Haugen BR, et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167-1214.
3. Frates MC, Benson CB, Charboneau JW, et al., Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q. 2006; 22: 231-238.
4. Wang C, Crapo LM,. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am. 1997; 26: 189-218.
5. Cibas ES, Ali SZ,. The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009; 132: 658-665.
6. Xing M, Haugen BR, Schlumberger M,. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013; 381: 1058-1069.
7. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954.
8. Nikiforov YE,. Molecular analysis of thyroid tumors. Mod Pathol. 2011; 24 (suppl 2): S34-S43.
9. Kimura ET, Nikiforova MN, Zhu Z, et al., High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63: 1454-1457.
10. Elisei R, Ugolini C, Viola D, et al., BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008; 93: 3943-3949.
11. Nikiforova MN, Kimura ET, Gandhi M, et al., BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88: 5399-5404.
12. Chiosea S, Nikiforova M, Zuo H, et al., A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol. 2009; 20: 122-126.
13. Ciampi R, Nikiforov YE,. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol. 2005; 16: 163-172.
14. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE,. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008; 93: 1600-1608.
15. Mitchell PS, Parkin RK, Kroh EM, et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105: 10513-10518.
16. Barondes SH, Cooper DN, Gitt MA, Leffler H,. Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994; 269: 20807-20810.
17. Cvejic D, Savin S, Paunovic I, et al., Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer Res. 1998; 18: 2637-2641.
18. Giannini R, Faviana P, Cavinato T, et al., Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid. 2003; 13: 765-770.
19. Bartolazzi A, Gasbarri A, Papotti M, et al., Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001; 357: 1644-1650.
20. Saggiorato E, De Pompa R, Volante M, et al., Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer. 2005; 12: 305-317.
21. Sapio MR, Guerra A, Posca D, et al., Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer. 2007; 14: 1089-1097.
22. Nikiforov YE, Ohori NP, Hodak SP, et al., Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011; 96: 3390-3397.
23. Filicori F, Keutgen XM, Buitrago D, et al., Risk stratification of indeterminate thyroid fine-needle aspiration biopsy specimens based on mutation analysis. Surgery. 2011; 150: 1085-1091.
24. Moses W, Weng J, Sansano I, et al., Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg. 2010; 34: 2589-2594.
25. Felli N, Fontana L, Pelosi E, et al., MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A. 2005; 102: 18081-18086.
26. Visone R, Russo L, Pallante P, et al., MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007; 14: 791-798.
27. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G,. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2012; 12: 27-33.
28. Yang Z, Yuan Z, Fan Y, Deng X, Zheng Q,. Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma. Mol Med Rep. 2013; 8: 1353-1358.
29. Zhang C, Zhang J, Zhang A, et al., PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol. 2010; 37: 1621-1626.
30. Zhou YL, Liu C, Dai XX, Zhang XH, Wang OC,. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas. Med Oncol. 2012; 29: 3360-3366.
31. Yu S, Liu Y, Wang J, et al., Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012; 97: 2084-2092.
32. Yip L, Kelly L, Shuai Y, et al., MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011; 18: 2035-2041.
33. Jikuzono T, Kawamoto M, Yoshitake H, et al., The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. Int J Oncol. 2013; 42: 1858-1868.
34. Stokowy T, Eszlinger M, Swierniak M,. Analysis options for high-throughput sequencing in miRNA expression profiling. BMC Res Notes. 2014; 7: 144.
35. Fuziwara CS, Kimura ET,. MicroRNA deregulation in anaplastic thyroid cancer biology. Int J Endocrinol. 2014; 2014: 743450.